Who We Are

We are a biotechnology company, founded in 2012 and focused on developing the next generation of cancer immunotherapies. With over 20 years of research and clinical experience in the field, we have obtained an IND for both solid and hematological malignancies with a product candidate pipeline that is built on a foundation of proprietary cancer-specific targets and novel delivery technologies that will change the way cancer is treated.

Copyright © 2018 Kiromic. All rights reserved.